Fr. 44.90

Everyday Miracles - Curing Multiple Sclerosis, Scleroderma, and Autoimmune Diseases by Hematopoietic Stem Cell Transplant

Anglais · Livre Relié

Expédition généralement dans un délai de 2 à 3 semaines (titre imprimé sur commande)

Description

En savoir plus










A life-changing treatment is conquering auto-immune disorders—why doesn’t anyone know about it? 

Thirty-five years ago, Dr. Richard Burt began a journey to treat chronic autoimmune diseases as they’d never been treated before. Using a treatment originally developed for leukemia but modified to be more gentle—a one-time combination of immune targeting drugs followed by a transplant of the patient’s blood stem cells—he has documented the successful and often dramatic reversal of multiple sclerosis, systemic sclerosis (scleroderma), chronic inflammatory demyelinating polyradiculoneuropathy (CIPD), neuromyelitis optica, and Crohn’s disease. 

After decades of study and randomized trials, his approach, which has been duplicated in other parts of the world, is finally being recognized as an effective means of reversing these “incurable” diseases. Some of his patients have been symptom-free for more than twenty years, and in this book Dr. Burt tells their stories alongside his own journey of developing and refining the treatment, known as hematopoietic stem cell transplant (HSCT) for autoimmune disorders. “These patients are the heroes,” Dr. Burt has said. “Their bodies and spirits faced unrelenting disease, and yet they fight valiantly against the suffering and obstacles.” 

What is HSCT? How does it work? What are the risks? Why aren’t more doctors talking about it? And why is it still out of reach for so many patients who could benefit from it? Dr. Burt answers these questions and many more. Written for the layperson, Everyday Miracles grants patients with autoimmune diseases and the people who love them insights into the revolutionary approach that could convert their life sentence into a one-time reversible illness.

A propos de l'auteur










DR. RICHARD K. BURT is a Fulbright Scholar, CEO of Genani Biotechnology, a tenured retired Professor at Northwestern, and current Scripps faculty. He pioneered America’s first hematopoietic stem cell transplant for autoimmune diseases like multiple sclerosis and scleroderma. Dr Burt has seven United States Patent and Trademark Office (USPTO) patents on using induced pluripotent stem (IPS) cells for aging and degenerative diseases.

Dr. Burt was awarded Leukemia Scholar of America, the Lupus Foundation of America Fidelitas Award, the van Bekkum Award by the European Society for Blood and Marrow Transplantation (EBMT), the Distinguished Clinical Achievement Award by the Clinical Research Forum, the EBMT Clinical Achievement Award, and the "Keys to the Vatican" in Rome. He has spoken at numerous conferences, universities, and institutions. Hospitals worldwide offer his stem cell protocols to patients.

Dr. Burt was recognized by Science Illustrated for accomplishing one of the Top 10 medical breakthroughs and by Scientific American as one of the Top 50 individuals for improving humanity and outstanding leadership. Dr Burt has written 150 medical / science articles, four medical textbooks, and two lay books: Everyday Miracles and Kill Switch.

Détails du produit

Auteurs Burt, Dr. Richard Burt, Richard Burt, Richard K. Burt
Edition Forefront Books
 
Langues Anglais
Format d'édition Livre Relié
Sortie 01.01.2023
 
EAN 9781637631256
ISBN 978-1-63763-125-6
Pages 256
Dimensions 237 mm x 161 mm x 25 mm
Poids 406 g
Catégorie Sciences naturelles, médecine, informatique, technique > Médecine > Général

Commentaires des clients

Aucune analyse n'a été rédigée sur cet article pour le moment. Sois le premier à donner ton avis et aide les autres utilisateurs à prendre leur décision d'achat.

Écris un commentaire

Super ou nul ? Donne ton propre avis.

Pour les messages à CeDe.ch, veuillez utiliser le formulaire de contact.

Il faut impérativement remplir les champs de saisie marqués d'une *.

En soumettant ce formulaire, tu acceptes notre déclaration de protection des données.